Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines

International Journal of Oncology

Volumn 30, Issue 2, 2007, Pages 393-401

  Naramoto, Hiroko ^a   Uematsu, Takashi ^a   Uchihashi, Takayuki ^a   Doto, Ryosuke ^a   Matsuura, Takashi ^a   Usui, Yohei ^a   Uematsu, Setsuko ^a   Li, Xianqi ^a   Takahashi, Masahiro ^a   Yamaoka, Minoru ^a   Furusawa, Kiyofumi ^a  

^a MATSUMOTO DENTAL UNIVERSITY   (Japan)

Author keywords

ABC transporter; MDR1; MRP1; MRP7; Multidrug resistance; Salivary gland cell adenocarcinoma; Squamous cell carcinoma

Indexed keywords

ABCC10 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; DOCETAXEL; DRUG DERIVATIVE; ESTRADIOL; ESTRADIOL 17 BETA GLUCURONIDE; ESTRADIOL-17 BETA-GLUCURONIDE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; TAXOID; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANIMAL; ARTICLE; BIOSYNTHESIS; CANCER TRANSPLANTATION; FEMALE; GENE EXPRESSION REGULATION; HEAD AND NECK TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE; MULTIDRUG RESISTANCE; NUDE MOUSE; SALIVARY GLAND TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM TRANSPLANTATION; RNA, MESSENGER; SALIVARY GLAND NEOPLASMS; TAXOIDS;

EID: 34047262177     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Cognetti F, Pinnaro P, Ruggeri EM, et al: Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer. J Clin Oncol 7: 829-837, 1989.
2. Bourhis J, Wilson G, Wibault P, et al: Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer. Laryngoscope 104: 468-472, 1994.
3. Tobias JS: Has chemotherapy proved itself in head and neck cancer? Br J Cancer 61: 649-651, 1990.
4. Chang G: Multidrug resistance ABC transporters. FEBS Lett 555: 102-105, 2003.
5. Belinsky MG, Chen ZS, Shchaveleva I, Zeng H and Kruh GD: Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res 62: 6172-6177, 2002.
6. Belinsky MG, Bain LJ, Balsara BB, Testa JR and Kruh GD: Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins. J Natl Cancer Inst 90: 1735-1741, 1998.
7. Bera TK, Lee S, Salvatore G, Lee B and Pastan I: MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Mol Med 7: 509-516, 2001.
8. Hopper E, Belinsky MG, Zeng H, Tosolini A, Testa JR and Kruh GD: Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer Lett 162: 181-191, 2001.
9. Tammur J, Prades C, Arnould I, et al: Two new genes from the human ATP-binding cassette transporter superfamily, ABCC11 and ABCC12, tandemly duplicated on chromosome 16q12. Gene 273: 89-96, 2001.
10. Yabuuchi H, Shimizu H, Takayanagi S and Ishikawa T: Multiple splicing variants of two new human ATP-binding cassette transporters, ABCC11 and ABCC12. Biochem Biophys Res Commun 288: 933-939, 2001.
11. Cole SP, Bhardwaj G, Gerlach JH, et al: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
12. Cui Y, Konig J, Buchholz JK, Spring H, Leier I and Keppler D: Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55: 929-937, 1999.
13. Koike K, Kawabe T, Tanaka T, et al: A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 157: 5475-5479, 1997.
14. Kool M, van der Linden M, De Haas M, et al: MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 96: 6914-6919, 1999.
15. Zaman GJ, Flens MJ, van Leusden MR, et al: The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91: 8822-8826, 1994.
16. Guo Y, Kotova E, Chen ZS, et al: MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′-dideoxycytidine and 9′-(2′- phosphonylmethoxyethyl)adenine. J Biol Chem 278: 29509-29514, 2003.
17. Jedlitschky G, Burchell B and Keppler D: The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 275: 30069-30074, 2000.
18. Schuetz JD, Connelly MC, Sun D, et al: MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5: 1048-1051, 1999.
19. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E and Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol 63: 351-358, 2003.
20. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG and Kruh GD: Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res 64: 4927-4930, 2004.
21. Uematsu T, Yamaoka M, Matsuura T, et al: P-glycoprotein expression in human major and minor salivary glands. Arch Oral Biol 46: 521-527, 2001.
22. Kostrzewa-Nowak D, Paine MJ, Wolf CR and Tarasiuk J: The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer 93: 89-97, 2005.
23. Liu Y, Peterson DA, Kimura H and Schubert D: Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem 69: 581-593, 1997.
24. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
25. Uematsu T, Hasegawa T, Hiraoka BY, et al: Multidrug resistance gene 1 expression in salivary gland adenocarcinomas and oral squamous-cell carcinomas. Int J Cancer 92: 187-194, 2001.
26. Smith PK, Krohn RI, Hermanson GT, et al: Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85, 1985.
27. Wiechelman KJ, Braun RD and Fitzpatrick JD: Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation. Anal Biochem 175: 231-237, 1988.
28. Hrycyna CA, Ramachandra M, Ambudkar SV, et al: Mechanism of action of human P-glycoprotein ATPase activity. Photochemical cleavage during a catalytic transition state using orthovanadate reveals cross-talk between the two ATP sites. J Biol Chem 273: 16631-16634, 1998.
29. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
30. Towbin H, Staehelin T and Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4354, 1979.
31. Kelley DJ, Pavelic ZP, Gapany M, et al: Detection of P-glycoprotein in squamous cell carcinomas of the head and neck. Arch Otolaryngol Head Neck Surg 119: 411-414, 1993.
32. Yokoyama H, Ishida T, Sugio K, Inoue T and Sugimachi K: Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival. Surg Today 29: 1141-1147, 1999.
33. Robey-Cafferty SS, Rutledge ML and Bruner JM: Expression of a multidrug resistance gene in esophageal adenocarcinoma. Correlation with response to chemotherapy and comparison with gastric adenocarcinoma. Am J Clin Pathol 93: 1-7, 1990.
34. Filipits M, Pohl G, Rudas M, et al: Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 23: 1161-1168, 2005.
35. Breuninger LM, Paul S, Gaughan K, et al: Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res 55: 5342-5347, 1995.
36. Zeng H, Bain LJ, Belinsky MG and Kruh GD: Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res 59: 5964-5967, 1999.
37. Chen ZS, Lee K and Kruh GD: Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 276: 33747-33754, 2001.
38. Holoye PY, Byers RM, Gard DA, Goepfert H, Guillamondegui OM and Jesse RH: Combination chemotherapy of head and neck cancer. Cancer 42: 1661-1669, 1978.
39. Petursson SR: Adenoid cystic carcinoma of the esophagus. Complete response to combination chemotherapy. Cancer 57: 1464-1467, 1986.
40. Zhang CC, Yang JM, Bash-Babula J, et al: DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4. Cancer Res 59: 3663-3670, 1999.
41. Zhang CC, Yang JM, White E, Murphy M, Levine A and Hait WN: The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. Oncogene 16: 1617-1624, 1998.